quinazolines has been researched along with Benign Cerebellar Neoplasms in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Alimova, I; Balakrishnan, I; Donson, A; Erlander, M; Foreman, NK; Fosmire, S; Joshi, M; Madhavan, K; Pierce, A; Ridinger, M; Sullivan, KD; Venkataraman, S; Veo, B; Vibhakar, R; Wang, D | 1 |
Bolin, S; Borgenvik, A; Bradner, JE; Cho, YJ; Persson, CU; Qi, J; Sundström, A; Swartling, FJ; Weishaupt, H; Weiss, WA | 1 |
Bebenek, M; Bryant, M; Diaz, RJ; Faria, C; Golbourn, B; Huang, A; Leadly, M; MacKenzie, D; Picard, D; Raynaud, D; Rutka, JT; Shih, D; Smith, CA; Taylor, MD | 1 |
Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
Abraham, J; Davare, MA; Giles, FJ; Hanes, MA; Keller, C; Kilcoyne, A; Lal, S; Nelon, LD; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP | 1 |
Fujii, Y; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
6 other study(ies) available for quinazolines and Benign Cerebellar Neoplasms
Article | Year |
---|---|
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Child; G2 Phase Cell Cycle Checkpoints; Humans; Medulloblastoma; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines | 2022 |
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Topics: Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Cyclin-Dependent Kinase 2; Drug Synergism; Female; Humans; Medulloblastoma; Piperazines; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Medulloblastoma; Mice, Nude; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |
Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Separation; Cerebellar Neoplasms; Disease Models, Animal; Flow Cytometry; Immunohistochemistry; Medulloblastoma; Mice; Mice, Transgenic; Piperazines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
[A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2006 |